share_log

NexImmune | NT 10-K: Others

NexImmune | NT 10-K: Others

NexImmune | NT 10-K:其他
SEC announcement ·  03/29 16:09
Moomoo AI 已提取核心訊息
NexImmune, Inc. has filed a Notification of Late Filing with the SEC, indicating that its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, will be delayed. The company attributes the delay to a significant reduction in workforce, which has left it with fewer resources to prepare and review the financial statements. Despite the reduction, key management and scientific team members remain to support ongoing business efforts. NexImmune expects to file the Form 10-K within the fifteen-day extension period allowed under Rule 12b-25 of the Securities Exchange Act. The company has also included forward-looking statements in the notification, cautioning that actual results may differ from current expectations due to risks and uncertainties. The notification was signed by CEO Kristi Jones on March 29, 2024.
NexImmune, Inc. has filed a Notification of Late Filing with the SEC, indicating that its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, will be delayed. The company attributes the delay to a significant reduction in workforce, which has left it with fewer resources to prepare and review the financial statements. Despite the reduction, key management and scientific team members remain to support ongoing business efforts. NexImmune expects to file the Form 10-K within the fifteen-day extension period allowed under Rule 12b-25 of the Securities Exchange Act. The company has also included forward-looking statements in the notification, cautioning that actual results may differ from current expectations due to risks and uncertainties. The notification was signed by CEO Kristi Jones on March 29, 2024.
NexImmune, Inc.已向美國證券交易委員會提交了逾期申報通知,表示其截至2023年12月31日財年的10-K表年度報告將被推遲。該公司將延遲歸因於員工人數的大幅裁員,這使其編制和審查財務報表的資源減少了。儘管有所減少,但主要管理層和科學團隊成員仍在支持正在進行的業務工作。NexImmune預計將在《證券交易法》第12b-25條允許的十五天延期內提交10-K表格。該公司還在通知中加入了前瞻性陳述,警告說,由於風險和不確定性,實際業績可能與當前的預期有所不同。該通知由首席執行官克里斯蒂·瓊斯於2024年3月29日簽署。
NexImmune, Inc.已向美國證券交易委員會提交了逾期申報通知,表示其截至2023年12月31日財年的10-K表年度報告將被推遲。該公司將延遲歸因於員工人數的大幅裁員,這使其編制和審查財務報表的資源減少了。儘管有所減少,但主要管理層和科學團隊成員仍在支持正在進行的業務工作。NexImmune預計將在《證券交易法》第12b-25條允許的十五天延期內提交10-K表格。該公司還在通知中加入了前瞻性陳述,警告說,由於風險和不確定性,實際業績可能與當前的預期有所不同。該通知由首席執行官克里斯蒂·瓊斯於2024年3月29日簽署。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息